Detalhe da pesquisa
1.
Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature.
Breast Cancer Res Treat
; 153(3): 617-24, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26358708
2.
Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study.
JCO Precis Oncol
; 8: e2400026, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38865672
3.
Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
JCO Precis Oncol
; 8: e2300513, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38354330
4.
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
J Clin Oncol
; : JCO2302078, 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38748939
5.
Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study.
JCO Precis Oncol
; 7: e2300041, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37315265
6.
Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
J Clin Oncol
; 41(33): 5140-5150, 2023 Nov 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37561967
7.
Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study.
JCO Precis Oncol
; 7: e2200609, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37027810
8.
Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
JCO Precis Oncol
; 7: e2300385, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-38096472
9.
Dual HER2-targeted approaches in HER2-positive breast cancer.
Breast Cancer Res Treat
; 131(2): 371-83, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21956210
10.
Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study.
JCO Precis Oncol
; 6: e2200306, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36315917
11.
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
JCO Precis Oncol
; 6: e2200191, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36409971
12.
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
J Clin Oncol
; 39(22): 2443-2451, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33844595
13.
Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Target Oncol
; 15(6): 743-750, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33068284
14.
Palbociclib in Patients With Non-Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
JCO Precis Oncol
; 4: 757-766, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35050752
15.
Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
JCO Precis Oncol
; 3: 1-8, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35100714
16.
Life-threatening hypercoagulable state following splenectomy in ITP: successful management with aggressive antithrombotic therapy and danazol.
Clin Appl Thromb Hemost
; 11(3): 347-52, 2005 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-16015423
17.
Improved clinical outcomes associated with vitamin D supplementation during adjuvant chemotherapy in patients with HER2+ nonmetastatic breast cancer.
Clin Breast Cancer
; 15(1): e1-11, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25241299
18.
Defining the survival benchmark for breast cancer patients with systemic relapse.
Breast Cancer (Auckl)
; 9: 9-17, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25922577
19.
Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk.
Thromb Res
; 114(2): 143-8, 2004.
Artigo
em Inglês
| MEDLINE | ID: mdl-15306157
20.
Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy.
Breast Cancer (Auckl)
; 6: 191-207, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-23226023